Previous 10 | Next 10 |
Arbutus Biopharma (ABUS) announces additional data from an ongoing Phase 1a/1b trial, AB-729-001, evaluating AB-729, its proprietary GalNAc delivered RNAi compound, for Chronic Hepatitis B virus infection.Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg (surface antigen...
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p<0.7) AB-729 remains generally safe and well tolerated with no SAEs o...
Corbus Pharmaceuticals Holdings (CRBP) +34%.China Automotive Systems (CAAS) +26%.Mogo (MOGO) +9% after reporting Bitcoin transaction volume for November.Dunxin Financial Holdings (DXF)+20% on signing agreement with Baite Biological Group.HEXO (HEXO) +19%.Neptune Wellness Soluti...
4 Penny Stocks to Watch Heading Into December With Black Friday in full effect, there are plenty of things for penny stock investors to be thankful for. In the past few weeks, we have seen solid momentum amongst a handful of penny stocks to watch. These penny stocks span different s...
Data released today expands on November 15, 2020 AASLD presentation Repeat dosing of 60 mg AB-729 every 4 weeks resulted in robust and continuous mean declines in HBsAg decline at week 20 (-1.71 log10IU/mL , N=7 ) and f urther reductio...
Arbutus Biopharma (ABUS) announces updated clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its GalNAc delivered RNAi compound in chronic hepatitis B infection. Single-doses of AB-729 studied to date, 60 mg, 90 mg and 180 mg, resulted in comparable mean HBsAg...
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted In the 60 mg every 4 week s multi-dose cohort...
5 Penny Stocks To Watch Before Thanksgiving November has already shown itself to be a promising month for penny stocks . With so many different penny stocks to choose from, there are a few ways to narrow down one’s list. For starters, investors have to identify what area of p...
WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includ...
Arbutus Biopharma Corporation (ABUS) Q3 2020 Earnings Conference Call November 5, 2020 08:45 ET Company Participants Pam Murphy - Investor Relations Bill Collier - President & Chief Executive Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike S...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...